Given the prevailing economic conditions, we are expecting company revenues to grow at a healthy rate, with a fairly steady gross margin in 2012. This will be driven mainly by the expected organic growth of the company.

 

With a large share of sales being generated in the MENA region, the company is likely to continue to benefit from the growth in the region’s pharmaceutical market, which is expected to remain much higher than that in the global market. Our share of the MENA market could also continue to increase as we consolidate our position in our existing markets, while expanding into new markets with our growing portfolio of products. With new products and new markets, we see considerable scope for us to grow our business, in the MENA region and beyond.

The company is likely to consolidate its position in MENA further, and is well-poised to continue to benefit from the growth opportunities available in the region’s pharmaceutical market

Our solid balance sheet, low gearing and continued focus on operating cash flow generation is likely to give us the financial flexibility to pursue growth opportunities, including strategic acquisitions that could supplement our strong organic growth. We are confident that the proven strength of Julphar’s business model will enable us to deliver a strong performance in 2012 and beyond.